LDK378 dihydrochloride 是一种选择性的、口服具有活性的、ATP 竞争性的ALK酪氨酸激酶抑制剂 (IC50:200 pM)。它还抑制IGF-1R (IC50:8 nM)，InsR (IC50:7 nM) 和 STK22D (IC50:23 nM)。它显示出良好的抗肿瘤作用。

Ceritinib dihydrochloride is a selective, orally bioavailable and ATP-competitive inhibitor of ALK tyrosine kinase(IC50 of 200 pM), and also inhibits IGF-1R, InsR, and STK22D (IC50 values of 8, 7, and 23 nM, respectively), shows great antitumor potency

In vitro experiments also showed that lipopolysaccharide (LPS)-induced migration of MDSCs was similarly owing to the activation of GRK2 and upregulation of CCR2 by LPS, whereas the treatment with LDK378 partially blocked the LPS-induced phosphorylation of p38 and GRK2 and decreased the expression of CCR2 on the cell surface, therefore leading to the suppression of MDSC migration[1].

LDK378 significantly improved the survival of CLP-induced polymicrobial septic mice, which was paralleled by reduced organ injury, decreased release of inflammatory cytokines and decreased recruitment of MDSCs to the spleen.?Importantly, LDK378 inhibited the migration of MDSCs to the spleen by blocking the CLP-mediated upregulation of CC chemokine receptor 2 (CCR2), a chemokine receptor critical for the recruitment of MDSCs.?Mechanistically, LDK378 treatment blocked the CLP-induced CCR2 upregulation of MDSCs via partially inhibiting the phosphorylation of p38 and G-protein-coupled receptor kinase-2 (GRK2) in bone marrow MDSCs of septic mice[1].

1380575-43-8

C28H38Cl3N5O3S

631.05

双盐酸盐色瑞替尼;LDK378 dihydrochloride

H2O:170 mg/mL (269.39 mM)
DMSO:95 mg/mL (150.54 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years